摘要
目的 改善儿童神经母细胞瘤预后。方法 对 14例神经母细胞瘤患儿用免疫组化方法检测N MYC蛋白 ,制定以分组分治为原则的诊断治疗方案 ,按方案中条件对不同危险度的患儿给予不同治疗。结果 14例中Ⅰ期 2例 ,Ⅱ期 0例 ,Ⅲ期 3例 ,Ⅳ期 9例。 2例进入低危组、4例进入中危组、8例进入高危组方案治疗。失访2例 ;持续缓解 3~ 2 6个月 7例 ,平均 15个月 ,占 5 8 3% (7/ 12 ) ;未获缓解或缓解后复发死亡 3例 ,平均生存期为14个月 ;部分缓解稳定 16个月 2例。N MYC阴性 7例 ,阳性 7例 ,与分期和是否获得持续缓解关系不明确。结论 对神经母细胞瘤进行分组分治是合理的原则 ,可以改善预后。N MYC蛋白的表达对预后的影响不明确。
Objective To improve the prognoses for children with neuroblastoma(NB) and to determine the effect on NB prognosis by N-MYC protein.Methods N-MYC protein was tested by immuno-histochemistry. Treatment protocol was designed depends on the risk group.Results There are 14 patients in total including 2 patients with stage Ⅰ disease, 3 with stage Ⅲ disease, 9 with stage Ⅳ disease. 2 cases were treated with the protocol for low risk group , 4 were treated with the protocol for middle risk and 8 with the protocol for high risk. Up to Mar.30, 2001, 2 lost following-up, 7 are in continue complete remission for 3~26 months, average 15 months accounting for 58%(7/12). 2 is surviving with stable residual disease for 16 months. 3 died of treatment failure after surviving 14 months average. 7 patients are positive with N-MYC protein, and another 7 are negative for N-MYC protein. Relationship between N-MYC and disease stage, prognosis has not been found. Conclusion The prognosis of neuroblastoma is improved in this study and it is reasonable to treat neuroblastoma depends on the risk group. No toxic death proved the safety of the protocol.
出处
《中国实用儿科杂志》
CSCD
北大核心
2002年第2期80-82,共3页
Chinese Journal of Practical Pediatrics
基金
上海市卫生局百人计划 (基金编号 98BR0 36 )
